Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia.


Sorry, we couldn't extract an abstract for this paper.
DOI: 10.1016/j.jval.2015.09.1188


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.